Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Summary

SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

Timeline

Start

2023-05-02

Primary completion

2025-11-04

Completion

2038-11-04

Drugs

Indications